Novavax COVID-19 Vaccine, Adjuvanted
Novavax COVID-19 Vaccine, Adjuvanted is available under EUA to prevent COVID-19 in individuals 18 years of age and older.
The vaccine is authorized for emergency use as a two-dose primary series. The two doses are given three weeks apart.
Novavax COVID-19 Vaccine, Adjuvanted contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. Adjuvants are incorporated into some vaccines to enhance the immune response of the vaccinated individual. The spike protein in this vaccine is produced in insect cells; the Matrix M-adjuvant contains saponin extracts from the bark of the Soapbark tree that is native to Chile.
Common Side Effects
The most commonly reported side effects by vaccine recipients included pain/tenderness, redness and swelling at the injection site, fatigue, muscle pain, headache, joint pain, nausea/vomiting and fever. Read more about side effects on the Fact Sheet for Recipients and Caregivers.
Fact Sheets (English)
Information | Last Updated |
---|---|
Fact Sheet for Healthcare Providers Administering Vaccine | July 13, 2022 |
Fact Sheet for Recipients and Caregivers | July 13, 2022 |
Regulatory Information
Information | Date |
---|---|
Letter of Authorization | July 13, 2022 |
Advisory Committee Meeting Information | June 7, 2022 |
Media Materials
Information | Date |
---|---|
Press Release | July 13, 2022 |
Advisory Committee Meeting Webcast | June 7, 2022 |